[ad_1]
-
Cantor Fitzgerald initiated protection on Sorrento Therapeutics Inc (NASDAQ: SRNE) with an Chubby ranking and a worth goal of $5.
-
The analyst says Sorrento has the potential to ship a number of best-in-class merchandise in high-value areas of oncology, ache, and infectious illness, highlighting three worth drivers:
-
Scilex’s potential in non-opioid ache. Its ache portfolio at the moment has marketed and pipeline applications, which may unlock additional significant worth.
-
Abivertinib’s potential in non-small cell lung most cancers
-
A conservative platform worth is believed to permit traders to be rewarded from present ranges over the close to time period and over the long term as different pipeline applications come to the fore.
-
-
In August, abivertinib confirmed important remedy advantages in 209 response-evaluable, closely pretreated NSCLC sufferers, with an ORR of 56.5%.
-
A big CR charge was seen with Abivertinib (5.3%) in comparison with AstraZeneca Plc’s (NASDAQ: AZN) Tagrisso (osimertinib) (0.5%), general survival of 28.2 months (versus Tagrisso’s median OS of 26.8 months).
-
Worth Motion: SRNE shares are down 0.95% at $1.57 on the final verify Wednesday.
Newest Scores for SRNE
|
Date |
Agency |
Motion |
From |
To |
|---|---|---|---|---|
|
Aug 2021 |
HC Wainwright & Co. |
Maintains |
Purchase |
|
|
Jan 2021 |
Alliance World Companions |
Initiates Protection On |
Purchase |
|
|
Jul 2020 |
HC Wainwright & Co. |
Maintains |
Purchase |
View Extra Analyst Scores for SRNE
View the Newest Analyst Scores
See extra from Benzinga
Do not miss real-time alerts in your shares – be part of Benzinga Professional without spending a dime! Strive the instrument that can enable you make investments smarter, sooner, and higher.
© 2022 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
Source link